Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 1 - Prevention and Early StagesElmar Stickeler, Bahriye Aktas, Annika Behrens, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and BiomarkersNina Ditsch, Elmar Stickeler, Annika Behrens, et al.
Breast Cancer Research and Treatment|June 11, 2016
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patientsAlexander Hein, Paul Gass, Christina Barbara Walter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Geburtshilfe Und Frauenheilkunde|June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast CancerRachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 1 - Prevention and Early StagesElmar Stickeler, Bahriye Aktas, Annika Behrens, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and BiomarkersNina Ditsch, Elmar Stickeler, Annika Behrens, et al.
Breast Cancer Research and Treatment|June 11, 2016
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patientsAlexander Hein, Paul Gass, Christina Barbara Walter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Geburtshilfe Und Frauenheilkunde|June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast CancerRachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Pageof 18